APLIF News and Press, Appili Therapeutics Inc From 09/14/20

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, Septem...

Company is committed to evaluating use of the broad-spectrum antiviral in the early treatment setting of COVID-19 to shorten the time to clinical recovery in adult patients with mild to moderate symptoms Investigators plan to recruit 826 participants in the randomized, placebo-control...

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its leadership team will be presenting an update on Appili’s programs at two upcoming investor conferences. A copy of...

Appili Therapeutics ( OTCQX:APLIF ) : FQ1 GAAP EPS of -C$0.05. As of June 30, 2020, the Company had cash and short-term investments of C$25.6M, compared to C$10.5M at March 31, 2020. Press Release More news on: Appili Therapeutics Inc., Earnings news and commentary, Healthcare stock...

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2021, which ended June 30, 2020. First quarter...

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced the voting results from its annual and special meeting of shareholders held on Thursday, August ...

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares listed in the United States, under the symbol APLIF, are Depository Trust Company (DTC) eligible. DTC is a...

The FDA has signed off on Appili Therapeutics's ( OTCQX:APLIF ) Investigational New Drug (IND) application for its broad-spectrum antiviral favipiravir for COVID-19. More news on: Appili Therapeutics Inc., Healthcare stocks news, Read more ...

U.S. expansion of antiviral outbreak control trial in long-term care facilities Favipiravir already approved in India and Russia for emergency use against COVID-19 and as a pandemic influenza antiviral medication in Japan First oral antiviral that may provide protection for elder...